Stockreport

ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy

ARCA biopharma, Inc.  (ABIO) 
US:NASDAQ Investor Relations: arcabio.com/investors
PDF AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID [Read more]